Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA.

Shen SY, Burgener JM, Bratman SV, De Carvalho DD

Circulating cell-free DNA (cfDNA) comprises small DNA fragments derived from normal and tumor tissue that are released into the bloodstream. Recently, methylation profiling of cfDNA as a liquid biopsy tool has been gaining prominence due to the presence of tissue-specific markers in cfDNA. We have previously reported cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) as a sensitive, low-input, cost-efficient and bisulfite-free approach to profiling DNA methylomes of plasma cfDNA. cfMeDIP-seq is an extension of a previously published MeDIP-seq protocol and is adapted to allow for methylome profiling of samples with low input (ranging from 1 to 10 ng) of DNA, which is enabled by the addition of 'filler DNA' before immunoprecipitation. This protocol is not limited to plasma cfDNA; it can also be applied to other samples that are naturally sheared and at low availability (e.g., urinary cfDNA and cerebrospinal fluid cfDNA), and is potentially applicable to other applications beyond cancer detection, including prenatal diagnostics, cardiology and monitoring of immune response. The protocol presented here should enable any standard molecular laboratory to generate cfMeDIP-seq libraries from plasma cfDNA in ~3-4 d.

MagMeDIP kit
IPure kit

Share this article

August, 2019


Products used in this publication

  • Mouse IgG
    5-methylcytosine (5-mC) Antibody - clone 33D3
  • Methylation kit icon
    DNA Methylation control package
  • default alt
    IPure kit v2
  • MagMeDIP qPCR Kit box
    MagMeDIP qPCR Kit
  • default alt
    MagMeDIP kit


  • APHL 2024
    Milwaukee, Wisconsin, USA
    May 6-May 9, 2024



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics